2480 Stock Overview
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Beijing Luzhu Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$20.65 |
| 52 Week High | HK$27.20 |
| 52 Week Low | HK$19.00 |
| Beta | -1.54 |
| 1 Month Change | -16.57% |
| 3 Month Change | -5.71% |
| 1 Year Change | -17.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -6.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2480 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -4.4% | -1.5% | 3.8% |
| 1Y | -17.1% | 39.9% | 14.6% |
Return vs Industry: 2480 underperformed the Hong Kong Biotechs industry which returned 39.9% over the past year.
Return vs Market: 2480 underperformed the Hong Kong Market which returned 14.6% over the past year.
Price Volatility
| 2480 volatility | |
|---|---|
| 2480 Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.5% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2480 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2480's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 159 | Jian Kong | luzhubiotech.com |
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine, which completed Phase III clinical trial; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis, that completed Phase I clinical trial; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma, which is in Phase I clinical trial. The company’s pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of varicella in children; Recombinant Syncytial Virus (RSV) vaccine for the indication of RSV-induced lower respiratory tract disease; Recombinant HSV-1 vaccine t targets oral herpes or cold sores; Recombinant HSV-2 vaccine targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 bispecific antibody to treat lymphoma.
Beijing Luzhu Biotechnology Co., Ltd. Fundamentals Summary
| 2480 fundamental statistics | |
|---|---|
| Market cap | HK$4.32b |
| Earnings (TTM) | -HK$182.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-22.8x
P/E RatioIs 2480 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2480 income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥168.24m |
| Earnings | -CN¥168.23m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 6.4% |
How did 2480 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 10:03 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beijing Luzhu Biotechnology Co., Ltd. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| Zhu Chen | Citic Securities Co., Ltd. |